Immune Onco is a tumor immunotherapy product developer. The company is mainly committed to the development and research of tumor immunotherapy products. The products developed include monoclonal antibodies against immunomodulatory targets and armed target-specific NK cells. Immune Onco Hong Kong Stock Exchange submitted its prospectus today.
This article is reprinted from: https://www.itjuzi.com/pre-ipo?comname=%E5%AE%9C%E6%98%8E%E6%98%82%E7%A7%91
This site is for inclusion only, and the copyright belongs to the original author.